Sector consensus Viking Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 01:30:00 20/05/2026 am IST			5-day change	1st Jan Change
28.40 ^USD	-1.01%		-9.32%	-19.27%

12/05	Viking Therapeutics, Inc. Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735	CI
12/05	Viking Therapeutics presents data from its 13-week phase 2 venture-oral dosing trial	RE

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Analysts' Target price divergence	Average Target P.	Objective/dr gap	Nbr of analysts
VIKING THERAPEUTICS, INC.			92.33	+225.12%	18
ARGENX SE			846.68	+23.6%	15
WUXI APPTEC CO., LTD.			145.41	+42.86%	17
INSMED INCORPORATED			201	+87.13%	20
BIONTECH SE			108.07	+42.72%	17
WUXI BIOLOGICS (CAYMAN) INC.			40.13	+39.47%	21
GENMAB A/S			2,313.13	+39.6%	15
AKESO, INC.			150.59	+53.14%	21
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.			533.85	+24.27%	17
EXELIXIS, INC.			49.65	+2.01%	17
SUMMIT THERAPEUTICS INC.			22.03	+86.18%	13
MADRIGAL PHARMACEUTICALS, INC.			674.36	+31.76%	14
ARROWHEAD PHARMACEUTICALS, INC.			88.17	+20.48%	12
PHARMAESSENTIA CORPORATION			778.83	-2.16%	6
IMMUNITYBIO, INC.			15.25	+96.52%	4
SAMSUNG EPIS HOLDINGS CO., LTD.	-	-	7,70,000	+60.75%	1
REMEGEN CO., LTD.			100.52	+36.29%	15
NUVALENT, INC.			142.05	+40.64%	18
BIOCON LIMITED			421.32	-1.6%	19
VAXCYTE, INC.			109	+123.45%	9
Average			38,841.62	+53.61%	14
Weighted average by Cap.			20,350.13	+44.41%	16